1. Scrip
  2. >>Business

Pfizer And ProFound Partner On Next-Generation Obesity Drugs

 
• By Jessica Merrill

Deal Snapshot: Pfizer will collaborate with the Flagship Pioneering-backed startup under a broader long-term partnership between the big pharma and venture capital firm.

handshake
Pfizer is partnering with Flagship's ProFound in obesity • Source: Shutterstock

Who: Flagship Pioneering/ProFound Therapeutics and Pfizer

What: Pfizer is partnering with a Flagship-founded company called ProFound, focused on expanding the human proteome, to identify next-generation, first-in-class...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Skyhawk Looks To Soar With Huntington’s Hope

 
• By Kevin Grogan

Oral RNA splicing modulator has gone into a Phase II/III trial

BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program

 
• By Sarah Karlin-Smith, Mandy Jackson, and Alaric DeArment

Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.

EY Recommends Focusing On Fundamentals, Waiting For Prime Deal Conditions

 
• By Joseph Haas

Government policy ramifications and tight financial markets mean it’s time to prepare strategically for a better business development environment, EY suggests.